Global Renal Cell Cancer (RCC) Disease Forecast and Market 2019-2038: Sutent Continues to be the Most Widely Prescribed Therapy in Locally Advanced and Metastatic RCC
Wednesday, June 19, 2019
DUBLIN, June 19, 2019 /PRNewswire/ -- The "Renal cell cancer (RCC) disease forecast and market analysis to 2038" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
Renal cell carcinoma (RCC) is a tumor that originates in the renal cortex, the outer part of the kidney between the renal capsule and the renal medulla. Around 85% of all malignant kidney tumors are RCC, with other types including transitional cell carcinoma of the renal pelvis and Wilms tumor (nephroblastoma).
The incidence of RCC is higher in those over the age of 60 years, suggesting that the aging population may play a significant role in current and future disease burden. Overall, RCC incidence rates have been steadily increasing in both men and women in the US, Japan, and five major EU markets since the 1970s.
Market Snapshot
-- The PD-1/PD-L1 class is set to experience significant growth, with
annual sales forecast to reach $3.2bn by 2026.
-- Sutent continues to be the most widely prescribed therapy in locally
advanced and metastatic RCC.
-- Incident cases of RCC are expected to increase by around a quarter
during 2018-38.
-- Numerous therapies will soon experience generic erosion with the
expiries of key patents.
-- PD-1/PD-L1 therapies are set to dominate the first-line treatment of
advanced RC
-- Combination therapies pose challenges for payers.
Key Topics Covered:
Overview
Recent Forecast Updates
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile: Afinitor
Product Profile: Avastin
Product Profile (Late Stage): Bavencio
Product Profile (Late Stage): Cb-839
Product Profile: Cabometyx
Product Profile: Fotivda
Product Profile: Inlyta
Product Profile (Late Stage): Keytruda
Product Profile: Lenvima
Product Profile: Nexavar
Product Profile: Opdivo
Product Profile: Sutent
Product Profile (Late Stage): Tecentriq
Product Profile: Torisel
Product Profile: Votrient
Product Profile (Late Stage): Abexinostat
Treatment: Renal Cell Carcinoma (Published On 16 February 2018)
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
Epidemiology: Renal Cell Carcinoma (Published On 06 March 2019)
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources
Marketed Drugs: Renal Cell Carcinoma (Published On 06 March 2019)
Overview
Product Overview
Product Profile: Afinitor
Product Profile: Avastin
Product Profile: Cabometyx
Product Profile: Fotivda
Product Profile: Inlyta
Product Profile: Lenvima
Product Profile: Nexavar
Product Profile: Opdivo
Product Profile: Sutent
Product Profile: Torisel
Product Profile: Votrient
Renal Cell Cancer Pricing, Reimbursement, And Access (Published On 22 August 2018)
Overview
Regulatory Labels
Global Access Levers
Evidence And Value
Access To Recently Approved And Pipeline Drugs
Pricing
US
Canada
Japan
France
Germany
Italy
Spain
UK
Methodology
Pipeline: Renal Cell Carcinoma (Published On 06 March 2019)
Overview
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Bavencio
Product Profile (Late Stage): Cb-839
Product Profile (Late Stage): Keytruda
Product Profile (Late Stage): Tecentriq
Product Profile (Late Stage): Abexinostat
For more information about this report visit https://www.researchandmarkets.com/r/2og07l
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/global-renal-cell-cancer-rcc-disease-forecast-and-market-2019-2038-sutent-continues-to-be-the-most-widely-prescribed-therapy-in-locally-advanced-and-metastatic-rcc-300871166.html
SOURCE Research and Markets
|
|
|
|
JND eDiscovery Receives National Law Journal Hall of Fame Award in Two Categories | Mar 29, 2024
|
|
Trip.com's Global 3.3 Promotion Sees Record Success in Asia and Europe | Mar 29, 2024
|
|
Europe Fibercos and Towercos Market Dynamics Report 2024: Lessons Learned and Key Takeaways for Telcos and Infrastructure Companies | Mar 29, 2024
|
|
China Non-Invasive Prenatal Testing Analysis Report 2024: Testing Volume 2018-2032 and Market Estimation Forecasts 2024-2032 with Focus on Mergers & Acquisitions, Collaborations, and Partnerships | Mar 29, 2024
|
|
Global Highly Potent API (Active Pharmaceutical Ingredient) Industry Research 2023-2033: Advancements in Containment Technologies, and Increasing Investment for Manufacturing Units | Mar 29, 2024
|
|
Exclusive Networks announces a major step in its growth strategy in APAC with NEXTGEN Group acquisition | Mar 29, 2024
|
|
United States Self-Monitoring Blood Glucose Devices Market Research 2023-2032: SMBG Devices and CGM Systems Surge - The Shift from Traditional Blood Glucose Meters | Mar 29, 2024
|
|
"Bleach: Brave Souls" Thousand-Year Blood War Zenith Summons: Reinforcements Featuring Meninas, Rangiku, and Yumichika Begins March 31 Alongside a Spring Festival Campaign | Mar 29, 2024
|
|
Evolution enters Delaware through Rush Street Interactive | Mar 29, 2024
|
|
IDTechEx Discusses the Sustainability of Electric Vehicle Fire Protection Materials | Mar 29, 2024
|
|
|